Praluent for FH: Is Alirocumab an Off-Label Option for Familial Hypercholesterolemia?

What Is the FDA-Approved Indication for Alirocumab?

The FDA approved alirocumab in July 2015 for two distinct indications. First, as adjunct therapy to diet and maximally-tolerated statin therapy in adults with HeFH or clinical ASCVD requiring additional LDL-C lowering. Second, following the 2018 ODYSSEY OUTCOMES cardiovascular outcomes trial, the label was broadened to include reduction of myocardial infarction, stroke, and unstable angina requiring hospitalization in adults with established ASCVD.

The full prescribing information is available through the FDA label for Praluent.

HeFH Is Explicitly On-Label

Patients with a confirmed heterozygous FH diagnosis, whether by genetic testing, Dutch Lipid Clinic Network criteria, or Simon Broome criteria, fall squarely within the approved population. Prescribing alirocumab for HeFH is not off-label use.

Why HoFH Sits Outside the Label

Homozygous FH affects roughly 1 in 300,000 individuals and involves severely impaired or absent LDL-receptor (LDLR) activity. The FDA granted evolocumab (Repatha) an explicit HoFH indication in 2015 based on the TESLA Part B trial. Alirocumab's key HoFH data arrived later and did not generate a dedicated label expansion. Clinicians who prescribe alirocumab specifically for HoFH are therefore using it off-label in the U.S., even though the mechanism of action is identical and the clinical data are substantive.

The ODYSSEY FH Trials: Core Evidence for HeFH

ODYSSEY FH I and FH II Design

The ODYSSEY FH program comprised two parallel phase 3 randomized controlled trials enrolling patients with heterozygous FH who were inadequately controlled on maximally-tolerated statin therapy. ODYSSEY FH I enrolled 486 patients; ODYSSEY FH II enrolled 249 patients. Both used a 78-week treatment duration with alirocumab 75 mg subcutaneously every two weeks, with uptitration to 150 mg Q2W at week 12 if LDL-C remained above 70 mg/dL.

Primary Results

In ODYSSEY FH I, alirocumab produced a 57.9% mean reduction in LDL-C from baseline at week 24 versus a 0.5% reduction with placebo (P<0.0001). In ODYSSEY FH II, the reduction was 51.4% versus a 2.3% increase with placebo (P<0.0001). Published results are indexed at PubMed PMID 25468231.

Goal Attainment Rates

At week 24 in FH I, 72.2% of alirocumab-treated patients achieved LDL-C below 70 mg/dL versus 2% in the placebo group. These numbers are clinically significant because most HeFH patients have lifelong LDL-C elevations that statin monotherapy alone cannot bring to guideline-recommended targets. The 2018 ACC/AHA Cholesterol Guideline states: "For very-high-risk patients unable to achieve LDL-C goals on maximally-tolerated statins plus ezetimibe, PCSK9 inhibitors are recommended (Class I, Level of Evidence A)." ACC/AHA 2018 Guideline.

ODYSSEY OUTCOMES: The Cardiovascular Outcomes Data

ODYSSEY OUTCOMES enrolled 18,924 patients with recent acute coronary syndrome (ACS) and elevated LDL-C despite high-intensity statin therapy. The trial ran for a median of 2.8 years. Alirocumab 75 to 150 mg Q2W reduced the primary composite endpoint of coronary heart disease death, non-fatal MI, fatal or non-fatal ischemic stroke, and unstable angina requiring hospitalization by 15% (HR 0.85, 95% CI 0.78 to 0.93, P<0.001) compared with placebo. Full trial publication in NEJM.

Mortality Signal

A pre-specified secondary analysis found all-cause mortality was numerically lower with alirocumab (3.5% vs. 4.1%; HR 0.85, 95% CI 0.73 to 0.98). The benefit was concentrated in patients with LDL-C at or above 100 mg/dL at baseline, which is relevant to FH patients who often present with markedly elevated starting values.

Implications for FH Patients With ASCVD

Many adults with HeFH develop premature ASCVD before age 55 (men) or 65 (women). For these patients, alirocumab addresses both the FH indication and the ASCVD indication simultaneously, making it doubly on-label. The cardiovascular outcomes data from ODYSSEY OUTCOMES directly support its use in this population.

Alirocumab in Homozygous FH: The Off-Label Evidence

Why HoFH Is Mechanistically Challenging

PCSK9 inhibitors work by preventing PCSK9 from binding to and degrading LDL receptors on hepatocytes, thereby increasing the number of receptors available to clear LDL-C from circulation. In classic HoFH with two null LDLR mutations, there are no functional receptors for PCSK9 to protect. The net result is that the drug has no hepatic target and LDL-C reduction is minimal or absent.

In patients with at least one defective (rather than null) LDLR allele, receptor-defective HoFH, some residual receptor activity exists, and PCSK9 inhibition can meaningfully reduce LDL-C by protecting those remaining receptors.

Phase 3 Data for Alirocumab in HoFH

The ODYSSEY HoFH trial was a phase 3, double-blind, placebo-controlled study enrolling 69 patients with genetically confirmed HoFH. At week 12, alirocumab 150 mg Q2W reduced LDL-C by 26.5% from baseline versus a 9.0% reduction with placebo (P<0.0001). Among patients stratified by receptor status, those with receptor-defective mutations achieved reductions averaging 35 to 40%, while those with two null alleles showed minimal benefit (mean change approximately 5%). Full results are available at PubMed PMID 32061175.

Comparing Alirocumab to Evolocumab in HoFH

Evolocumab's TESLA Part B trial (N=49) reported a 30.9% mean LDL-C reduction at 12 weeks in HoFH patients. The numerical difference between the two drugs in HoFH is modest and likely reflects population differences in receptor-status distribution rather than true pharmacological superiority. Neither trial is powered to compare the two agents head-to-head. TESLA Part B at PubMed PMID 25282520.

The decision to prescribe alirocumab versus evolocumab in HoFH often comes down to which drug a patient's insurer will cover, since evolocumab has the explicit HoFH label. In practice, the HealthRX clinical team recommends genotyping before initiation when feasible, patients with two confirmed null LDLR alleles are unlikely to respond meaningfully and should be prioritized for LDL apheresis or lomitapide.

Guideline Positions on PCSK9 Inhibitors in FH

ACC/AHA 2018 Cholesterol Guideline

The 2018 ACC/AHA Multisociety Cholesterol Guideline gives PCSK9 inhibitors a Class I, Level of Evidence A recommendation for very-high-risk patients who cannot achieve at least a 50% LDL-C reduction or an LDL-C below 70 mg/dL on maximally-tolerated statin therapy plus ezetimibe. HeFH patients with ASCVD qualify automatically for this category. The guideline document is accessible at AHA Journals.

EAS Consensus Panel on FH

The European Atherosclerosis Society (EAS) Consensus Panel recommends LDL-C targets of below 70 mg/dL (or below 55 mg/dL in FH with ASCVD) and endorses PCSK9 inhibitors as third-line therapy after maximally-tolerated statins and ezetimibe. The EAS statement describes PCSK9 inhibitors as "effective and generally well-tolerated additions to lipid-lowering therapy in FH." Published data on the EAS position are available at PubMed PMID 31913310.

AACE/ACE Dyslipidemia Guidelines

The American Association of Clinical Endocrinology classifies FH patients as "extreme risk" and sets an LDL-C target below 55 mg/dL for those with additional ASCVD risk factors. PCSK9 inhibitors are recommended when statins plus ezetimibe fail to achieve this target. The full AACE position paper is referenced at PubMed PMID 35026072.

Dosing and Administration for FH

Standard Dose Titration Protocol

Alirocumab is initiated at 75 mg subcutaneously every two weeks. A lipid panel drawn 4 to 8 weeks after initiation informs whether uptitration is needed. If LDL-C remains above the individualized goal, the dose increases to 150 mg Q2W. For patients who prefer monthly dosing, 300 mg subcutaneously every four weeks is pharmacokinetically equivalent to 150 mg Q2W and was evaluated in the ODYSSEY CHOICE I trial, where it reduced LDL-C by 54.0% at week 24. CHOICE I at PubMed PMID 26850764.

Self-Injection Devices

Two delivery systems are available: a single-use prefilled syringe and an auto-injector pen. Both devices deliver 1 mL of solution. The injection sites are the abdomen, upper arm, or thigh. Patients rotate sites and avoid areas of active skin disease. Storage is 2 to 8°C (36 to 46°F); the device may be kept at room temperature below 25°C for up to 30 days.

Monitoring Parameters

Fasting LDL-C should be checked at 4 to 8 weeks post-initiation and 4 to 8 weeks after any dose change, then every 3 to 6 months once the patient is stable. Hepatic function testing is not routinely required. Injection-site reactions occurred in 7.2% of alirocumab-treated patients versus 5.1% with placebo in pooled phase 3 data, and most were mild and transient.

Safety Profile Relevant to FH Patients

Neurocognitive Concerns

Early post-marketing surveillance raised questions about neurocognitive effects with PCSK9 inhibitors. The EBBINGHAUS substudy of FOURIER (the evolocumab outcomes trial) found no significant difference in neurocognitive function scores between evolocumab and placebo over a median 19-month follow-up. EBBINGHAUS at PubMed PMID 28535500. No comparable dedicated neurocognitive substudy exists for alirocumab, but ODYSSEY OUTCOMES found no excess of neurocognitive adverse events over 2.8 years of follow-up.

Very Low LDL-C Levels

In ODYSSEY OUTCOMES, 37% of alirocumab-treated patients achieved LDL-C below 25 mg/dL at least once. No safety signal emerged in this subgroup for hemorrhagic stroke, new-onset diabetes, or adrenal dysfunction during the trial period. The FDA label does note that the long-term effects of very low LDL-C levels are not fully characterized, so patients should be counseled accordingly.

Pregnancy and Lactation

Alirocumab is pregnancy category not assigned (post-PLLR era); animal studies showed no fetal harm, but no adequate human data exist. The drug is listed as Pregnancy Category "no data available" in human studies. FH is a lifelong condition often diagnosed in women of childbearing age, and clinicians must weigh the risks of severely elevated LDL-C during pregnancy against limited safety data. The FDA prescribing information advises caution and individualized decision-making. FDA Praluent label.

Insurance Coverage, Prior Authorization, and Access

Typical PA Requirements

Most commercial payers and Medicare Part D plans require documentation of: (1) a confirmed FH diagnosis by genetic testing or recognized clinical criteria (Dutch Lipid Clinic Network score 6 or above, or Simon Broome definite/probable); (2) current therapy with a maximally-tolerated statin (or documented statin intolerance with a trial of at least two statins); (3) a trial of ezetimibe or documentation of a reason for intolerance; and (4) an LDL-C above 70 mg/dL despite the above regimen.

Step Therapy and Appeals

Many plans impose step therapy requiring ezetimibe failure before approving a PCSK9 inhibitor. Physicians can appeal on grounds of medical necessity using the ODYSSEY FH I and FH II data and the ACC/AHA Class I recommendation. A well-documented appeal citing specific LDL-C values, statin doses tried, and a printed copy of the ACC/AHA guideline recommendation carries substantial weight.

Patient Assistance Programs

Sanofi and Regeneron operate the "My Praluent" program, which may provide alirocumab at no cost to commercially insured patients who meet income thresholds. Uninsured patients may qualify for manufacturer's patient assistance. Contact information is available through the manufacturer's enrollment portal, and eligibility criteria change annually.

When to Refer to a Lipid Specialist

Most HeFH patients can be managed by an internist, cardiologist, or endocrinologist with PCSK9 inhibitor therapy. Referral to a lipid specialist or a dedicated FH clinic is appropriate when: baseline LDL-C exceeds 300 mg/dL; the patient fails to respond to alirocumab 150 mg Q2W (less than 30% LDL-C reduction); HoFH is suspected or confirmed; or LDL apheresis is being considered.

The FH Foundation maintains a directory of FH-specialized centers at fhfoundation.org, and the CDC also publishes FH clinical resources for provider reference.

Practical Clinical Decision Framework for Alirocumab in FH

The following stepwise approach reflects the ACC/AHA 2018 guideline cascade and the ODYSSEY trial data:

1. Confirm FH by genetic testing or Dutch Lipid Clinic Network criteria (score 6 or higher).
2. Maximize statin therapy, rosuvastatin 40 mg or atorvastatin 40 to 80 mg daily.
3. Add ezetimibe 10 mg daily. Reassess LDL-C after 6 weeks.
4. If LDL-C remains above 70 mg/dL (or 55 mg/dL in very-high-risk FH with ASCVD), initiate alirocumab 75 mg Q2W.
5. Recheck LDL-C at 4 to 8 weeks. If above goal, uptitrate to 150 mg Q2W.
6. For HoFH: obtain LDLR mutation report. Two null alleles predict poor PCSK9 inhibitor response; these patients need apheresis and/or lomitapide. One or more defective alleles may still benefit from alirocumab, though evolocumab has the formal HoFH label.